CA2724562A1 - Novel dual targeting antitumoural conjugates - Google Patents

Novel dual targeting antitumoural conjugates Download PDF

Info

Publication number
CA2724562A1
CA2724562A1 CA2724562A CA2724562A CA2724562A1 CA 2724562 A1 CA2724562 A1 CA 2724562A1 CA 2724562 A CA2724562 A CA 2724562A CA 2724562 A CA2724562 A CA 2724562A CA 2724562 A1 CA2724562 A1 CA 2724562A1
Authority
CA
Canada
Prior art keywords
formula
absent
mmol
compounds
tumour
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2724562A
Other languages
English (en)
French (fr)
Inventor
Alma Dal Pozzo
Emiliano Esposito
Minghong Ni
Sergio Penco
Claudio Pisano
Massimo Castorina
Loredana Vesci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of CA2724562A1 publication Critical patent/CA2724562A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2724562A 2008-05-20 2009-05-11 Novel dual targeting antitumoural conjugates Abandoned CA2724562A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08156575 2008-05-20
EP08156575.6 2008-05-20
PCT/EP2009/055653 WO2009141240A1 (en) 2008-05-20 2009-05-11 Novel dual targeting antitumoural conjugates

Publications (1)

Publication Number Publication Date
CA2724562A1 true CA2724562A1 (en) 2009-11-26

Family

ID=39765065

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2724562A Abandoned CA2724562A1 (en) 2008-05-20 2009-05-11 Novel dual targeting antitumoural conjugates

Country Status (16)

Country Link
US (1) US20110160147A1 (https=)
EP (1) EP2285396A1 (https=)
JP (1) JP2011523415A (https=)
KR (1) KR20110022594A (https=)
CN (1) CN102036676A (https=)
AR (1) AR071840A1 (https=)
AU (1) AU2009249795A1 (https=)
BR (1) BRPI0911978A2 (https=)
CA (1) CA2724562A1 (https=)
EA (1) EA201071326A1 (https=)
IL (1) IL208920A0 (https=)
MX (1) MX2010012320A (https=)
NZ (1) NZ588948A (https=)
TW (1) TW201004647A (https=)
WO (1) WO2009141240A1 (https=)
ZA (1) ZA201009036B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7985401B2 (en) 2003-10-31 2011-07-26 The Regents Of The University Of California Peptides whose uptake by cells is controllable
CA2770980A1 (en) 2009-07-15 2011-01-20 Roger Y. Tsien Peptides whose uptake in cells is controllable
CA2816041C (en) * 2010-12-29 2019-01-08 Arrowhead Research Corporation In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
CA2841249C (en) 2011-07-29 2023-09-26 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
US10029017B2 (en) 2013-01-29 2018-07-24 The Regents Of The University Of California Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug
EA031930B1 (ru) 2013-01-30 2019-03-29 Авелас Байосайенсиз, Инк. Молекула селективной доставки для визуализации злокачественной ткани
CN103333227B (zh) * 2013-06-07 2015-10-07 东南大学 转移肿瘤缺失蛋白小分子环肽抑制剂及其制备方法与应用
WO2015095227A2 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
WO2016008112A1 (en) * 2014-07-16 2016-01-21 Medshine Discovery Inc. Linkers and application towards adc thereof
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
US10125124B2 (en) 2015-03-20 2018-11-13 Massachusetts Institute Of Technology Formation of macromolecules using iterative growth and related compounds
US10596259B2 (en) 2015-05-20 2020-03-24 The Regents Of The University Of California Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof
CN108064246A (zh) 2015-06-15 2018-05-22 基因泰克公司 抗体和免疫结合物
EA202191244A1 (ru) * 2018-11-05 2021-10-11 Байер Фарма Акциенгезельшафт Новые цитостатические конъюгаты с лигандами интегрина

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2370245A1 (en) * 1999-05-14 2000-11-23 Boehringer Ingelheim Pharmaceuticals, Inc. Enzyme-activated anti-tumor prodrug compounds
ITRM20040240A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 7 con antagonisti delle integrine.
US8404650B2 (en) * 2005-10-28 2013-03-26 The Regents Of The University Of Colorado, A Body Corporate Methods of treating cancer with doxazolidine and prodrugs thereof

Also Published As

Publication number Publication date
TW201004647A (en) 2010-02-01
CN102036676A (zh) 2011-04-27
EA201071326A1 (ru) 2011-06-30
JP2011523415A (ja) 2011-08-11
MX2010012320A (es) 2010-12-01
NZ588948A (en) 2011-10-28
ZA201009036B (en) 2012-01-25
IL208920A0 (en) 2011-01-31
AU2009249795A1 (en) 2009-11-26
WO2009141240A1 (en) 2009-11-26
KR20110022594A (ko) 2011-03-07
US20110160147A1 (en) 2011-06-30
EP2285396A1 (en) 2011-02-23
BRPI0911978A2 (pt) 2019-09-24
AR071840A1 (es) 2010-07-21

Similar Documents

Publication Publication Date Title
US20110160147A1 (en) Novel dual targeting antitumoral conjugates
US6232468B1 (en) Dipeptides with neurokinin-antagonistic activity
HUT75708A (en) Neurokinine (tachykinine) antagonists
JP2005538035A (ja) グアニジニウム輸送試薬および結合体
IL99628A (en) Processes for the preparation of cyclic peptides, and pharmaceutical compositions containing them
CZ198497A3 (en) Cyclic peptides inhibiting fibronectin adhesion, process of their preparation and pharmaceutical compositions containing thereof
HU186749B (en) Process for preparing new, biologically active peptides
PL185762B1 (pl) Nowe peptydy stanowiące pochodne dolastatyny, ichzastosowanie w medycynie oraz kompozycja farmaceutyczna
US6235876B1 (en) Liquid phase process for the preparation of GNRH peptides
JPS62207251A (ja) オリゴペプチジルニトリル誘導体
AU744425B2 (en) 20(s) camptothecin glycoconjugates
US11319341B2 (en) Immune-stimulating soluble doxorubicin-conjugated complex
JP4615221B2 (ja) ヘプタペプチドオキシトシンアナログを製造するための中間体及び方法
US20100093612A1 (en) Integrin targeted cyclopeptide ligands, their preparation and use
ES2338164T3 (es) Compuestos para la inhibicion de la apoptosis.
EP1593686B1 (en) Antineoplastic peptides
SK62998A3 (en) New lh-rh antagonists with improved effectiveness
RU2286169C1 (ru) Семейство пептидов, обладающее анальгетической активностью
WO1997010261A1 (fr) Derives peptidiques
Abo-Ghalia et al. Optimized conventional synthesis of “RGD” and “RGDS” peptides and their sarcosine mimics as integrin GP IIb/IIIa antagonists
HK1155363A (en) Novel dual targeting antitumoural conjugates
WO2006097774A1 (en) Synthetic peptides containing unnatural adamantane-related amino acids for use as antitumour drugs
CA3208877A1 (en) Cryptophycin compounds and conjugates thereof
FI75579B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbar polypeptid.
ES2354320B2 (es) Ciclopéptidos marcados magnéticamente con complejos de lantánidos.

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140513